Too many people are running out of options
When Alana was diagnosed with acute myeloid leukaemia (AML), one of the deadliest blood cancers, treatment started immediately. After months of chemotherapy, she went into remission and began looking forward to the future again.
But then the cancer came back.
Alana joined a clinical trial that gave her and her loved ones hope that a new treatment might work. Sadly, it wasn't enough.
Today, only around 1 in 3 people survive the deadliest blood cancers, including AML. Too many people still run out of treatment options.
Donate today to help fund research and clinical trials that could give more people more time, more hope and more options.
Every gift helps create options, time and hope for people facing the deadliest blood cancers.
Join the incredible supporters who are funding research and saving lives.
Alana's Story
Alana loved making plans. Whether it was pub garden afternoons, trips to the beach or days out in London with friends, she was always looking ahead.
At the end of 2023, she thought she had flu. But she didn't get better. A few days later, she was rushed to hospital and diagnosed with AML.
After chemotherapy, Alana went into remission. She graduated and started enjoying life again. Then the cancer returned.
Her best friend Katie said:
"It meant everything to us to know there was still something left to try."
When no further treatments were available, Alana married her partner Charlie in a wedding organised in just five days. A few weeks later, she died surrounded by the people she loved.
Because people with blood cancer can't wait
We've launched a new research strategy, with a plan to double our investment in new research awards to £70 million over the next five years. Thanks to your support, we know we can get there.